Letrozole Tablet, Film Coated
Product Images NDC 17856-0032

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 17856-0032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Letrozole Label (17856 0032 01)

Letrozole 2.5 mg film-coated tablets label from Atlantic Biologicals Corp. The label includes dosage strength 2.5 mg, quantity of 100 tablets, and storage instructions to keep at 25°C (77°F) with permitted excursions to 30°C (86°F). It shows product NDC 17856-0032-01 with barcode, serial number, expiration date 06/26/20, and lot number 008898.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A line graph comparing Letrozole and Tamoxifen treatments over 72 months. The graph shows the proportion of patients over time, with separate lines for Letrozole (solid) and Tamoxifen (dashed). Data tables below list patient counts at risk at various months for both treatments.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A survival curve chart depicting progression-free status over time in months comparing Letrozole 2.5 mg tablets versus Tamoxifen 20 mg. The y-axis represents progression-free proportion, and the x-axis represents time in months, showing decreasing progression-free rates for both treatments over approximately 60 months.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A survival curve chart comparing the proportion of patients alive over time in months, with separate lines for letrozole and tamoxifen treatments. The x-axis represents time in months up to 60, and the y-axis shows the fraction alive, ranging from 0 to 1.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A Kaplan-Meier survival curve chart depicting time to progression in days on the x-axis and proportion remaining progression-free on the y-axis. The chart compares three treatment groups: Letrozole 0.5 mg tablet, Letrozole 2.5 mg tablet, and MA (presumably a control or comparator). The curves show progression over time for each group.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A Kaplan-Meier survival curve chart depicting time to progression (in days) for treatment groups receiving different doses of Letrozole tablets (0.5 mg and 2.5 mg) compared to a group labeled AG. The x-axis shows time to progression in days, and the y-axis shows the proportion without progression.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure diagram of letrozole, showing molecular bonds and rings consistent with its known molecular composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.